Retiro De Equipo (Recall) de ARCHITECT Lactic Acid. An in vitro diagnostic medical device (IVD)

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Abbott Australasia Pty Ltd Diagnostic Division.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
  • ID del evento
  • Clase de Riesgo del Evento
    Class II
  • Fecha de inicio del evento
  • País del evento
  • Fuente del evento
  • URL de la fuente del evento
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Negative interference has been detected from the drug n-acetyl cysteine (nac) used with the architect lactic acid reagent (ln 9d89-21). the customer letter identifies the levels of interference observed at nac concentrations of 80 mg/l (0.49 mmol/l) and 800 mg/l (4.9 mmol/l). patients undergoing treatment with nac may have falsely depressed lactic acid results. a falsely depressed result may lead a physician to mistakenly rule out lactic acidosis.
  • Acción
    Take into account the newly provided interference levels when using the device. This action has been closed out on 14 June 2017.


  • Modelo / Serial
    ARCHITECT Lactic Acid. An in vitro diagnostic medical device (IVD)List Number: 9D89-21Lot Number: 31497UN14 Expiry: 17-Oct-2016Lot Number: 09353UN15 Expiry: 12 Feb 2017Lot Number: 45216UN15 Expiry: 12 May 2017Lot Number: 14596UN15 Expiry: 30 Jul 2017Lot Number: 37055UN15 Expiry: 12 Oct 2017Lot Number: 14782UN16 Expiry: 21 Apr 2018ARTG Number: 185778
  • Manufacturer


  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source